
Wockhardt expands novel antibiotic Miqnaf's access; Q2 revenue rises 24%
Benchmarks Nifty23,440.80387.71FEATURED FUNDS★★★★★UTI Aggressive Hybrid Fund Regular Plan-Growth5Y Return9.02 % Invest NowFEATURED FUNDS★★★★★Motilal Oswal Midcap Fund Direct-Growth5Y Return18.55 % Invest NowEnter search…
Read report ↗









